CVS Caremark announced it will restore coverage for Eli Lilly's weight loss drug Zepbound this year, reversing a decision made in 2024 to remove the medication from its list of covered drugs. The pharmacy benefit manager's initial removal of coverage had prompted significant backlash from patients.

Zepbound, manufactured by Eli Lilly, is an anti-obesity medication that has gained attention as part of a new generation of weight loss treatments. The drug's temporary removal from CVS coverage had left many patients without insurance support for the medication.

In addition to restoring Zepbound coverage, CVS plans to add Eli Lilly's obesity pill to its drug formularies, expanding access to the company's weight management treatments. The decision reflects growing recognition of obesity medications as legitimate medical treatments requiring insurance coverage.

Meanwhile, in a separate development, France has become the first European Union country to provide reimbursement for anti-obesity drugs, according to French health officials. This move signals broader acceptance of obesity medications as essential healthcare treatments across different healthcare systems.

The restoration of coverage comes amid increasing demand for weight loss medications and ongoing debates about insurance coverage for obesity treatments. Patient advocacy and public pressure appear to have influenced CVS's decision to reverse its previous policy on Zepbound coverage.